139 related articles for article (PubMed ID: 36744336)
1. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.
Voss T; Kost J; Mercer SP; Furtek C; Randolph C; Lines C; Egan MF; Cummings JL
J Alzheimers Dis; 2023; 92(1):341-348. PubMed ID: 36744336
[TBL] [Abstract][Full Text] [Related]
2. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
[TBL] [Abstract][Full Text] [Related]
3. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
Doggrell SA
Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
[No Abstract] [Full Text] [Related]
4. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
5. Souvenaid for Alzheimer's disease.
Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
[TBL] [Abstract][Full Text] [Related]
6. Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.
Schneider LS; Bennett DA; Farlow MR; Peskind ER; Raskind MA; Sano M; Stern Y; Haneline S; Welsh-Bohmer KA; O'Neil J; Walter R; Maresca S; Culp M; Alexander R; Saunders AM; Burns DK; Chiang C
J Prev Alzheimers Dis; 2022; 9(4):625-634. PubMed ID: 36281666
[TBL] [Abstract][Full Text] [Related]
7. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
[TBL] [Abstract][Full Text] [Related]
8. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
Wessels AM; Dowsett SA; Sims JR
J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
[TBL] [Abstract][Full Text] [Related]
9. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
[TBL] [Abstract][Full Text] [Related]
10. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF
J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
12. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
[TBL] [Abstract][Full Text] [Related]
13. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
[TBL] [Abstract][Full Text] [Related]
14. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Isaac MG; Clark AR; Rusted J; Tabet N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002854. PubMed ID: 23152215
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
18. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
[TBL] [Abstract][Full Text] [Related]
19. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
20. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
